NO323610B1 - Polypeptider og peptider som omfatter en hemoglobin-alfa-kjede eller deler derav, farmasoytiske blandinger som omfatter dem, samt anvendelser og fremgangsmater som involverer stamcelleproliferasjonsinhiberende og -stimulerende mengder av polypeptidene og peptidene. - Google Patents

Polypeptider og peptider som omfatter en hemoglobin-alfa-kjede eller deler derav, farmasoytiske blandinger som omfatter dem, samt anvendelser og fremgangsmater som involverer stamcelleproliferasjonsinhiberende og -stimulerende mengder av polypeptidene og peptidene. Download PDF

Info

Publication number: NO323610B1
Authority: NO; Norway
Prior art keywords: hemoglobin; cells; chain; polypeptide; stem cell
Prior art date: 1996-04-03

Application number

NO19984628A

Other languages

English (en)

Norwegian (no)

Other versions

NO984628L (no

NO984628D0 (no

Inventor

Irena Tsyrlova

Stephen D Wolpe

Original Assignee

Pro Neuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-03

Filing date

1998-10-02

Publication date

2007-06-18

1998-10-02 Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc

1998-10-02 Publication of NO984628D0 publication Critical patent/NO984628D0/no

1998-12-01 Publication of NO984628L publication Critical patent/NO984628L/no

2007-06-18 Publication of NO323610B1 publication Critical patent/NO323610B1/no

Links

210000000130 stem cell Anatomy 0.000 title claims abstract description 277
238000000034 method Methods 0.000 title claims abstract description 75
230000004663 cell proliferation Effects 0.000 title claims abstract description 29
108090000765 processed proteins & peptides Proteins 0.000 title claims description 181
102000004196 processed proteins & peptides Human genes 0.000 title claims description 141
229920001184 polypeptide Polymers 0.000 title claims description 90
230000002401 inhibitory effect Effects 0.000 title claims description 59
230000004936 stimulating effect Effects 0.000 title claims description 44
108091005902 Hemoglobin subunit alpha Proteins 0.000 title claims description 16
102100027685 Hemoglobin subunit alpha Human genes 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title description 4
238000002512 chemotherapy Methods 0.000 claims abstract description 30
210000004976 peripheral blood cell Anatomy 0.000 claims abstract description 7
210000004027 cell Anatomy 0.000 claims description 156
241000282414 Homo sapiens Species 0.000 claims description 102
108010054147 Hemoglobins Proteins 0.000 claims description 80
102000001554 Hemoglobins Human genes 0.000 claims description 80
238000012360 testing method Methods 0.000 claims description 72
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 71
239000000203 mixture Substances 0.000 claims description 64
238000011282 treatment Methods 0.000 claims description 59
150000001413 amino acids Chemical class 0.000 claims description 57
102000005962 receptors Human genes 0.000 claims description 31
108020003175 receptors Proteins 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 30
238000002360 preparation method Methods 0.000 claims description 30
101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 claims description 28
150000001875 compounds Chemical class 0.000 claims description 26
229940079593 drug Drugs 0.000 claims description 21
230000014509 gene expression Effects 0.000 claims description 21
102000004127 Cytokines Human genes 0.000 claims description 20
108090000695 Cytokines Proteins 0.000 claims description 20
108010002386 Interleukin-3 Proteins 0.000 claims description 19
102000000646 Interleukin-3 Human genes 0.000 claims description 19
206010028980 Neoplasm Diseases 0.000 claims description 19
-1 IL-14 Proteins 0.000 claims description 18
210000004899 c-terminal region Anatomy 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 18
108090000848 Ubiquitin Proteins 0.000 claims description 17
210000002798 bone marrow cell Anatomy 0.000 claims description 17
230000002209 hydrophobic effect Effects 0.000 claims description 17
230000005855 radiation Effects 0.000 claims description 17
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 15
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 15
102000044159 Ubiquitin Human genes 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 15
239000000463 material Substances 0.000 claims description 14
102000014702 Haptoglobin Human genes 0.000 claims description 13
108050005077 Haptoglobin Proteins 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 13
230000004224 protection Effects 0.000 claims description 13
210000004700 fetal blood Anatomy 0.000 claims description 12
230000010261 cell growth Effects 0.000 claims description 11
230000004927 fusion Effects 0.000 claims description 11
230000003394 haemopoietic effect Effects 0.000 claims description 11
102000003951 Erythropoietin Human genes 0.000 claims description 10
108090000394 Erythropoietin Proteins 0.000 claims description 10
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 10
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 10
201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
238000012217 deletion Methods 0.000 claims description 10
230000037430 deletion Effects 0.000 claims description 10
229940105423 erythropoietin Drugs 0.000 claims description 10
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 10
108010002586 Interleukin-7 Proteins 0.000 claims description 9
230000002062 proliferating effect Effects 0.000 claims description 9
108700014844 flt3 ligand Proteins 0.000 claims description 8
238000001415 gene therapy Methods 0.000 claims description 8
208000030507 AIDS Diseases 0.000 claims description 7
241000588724 Escherichia coli Species 0.000 claims description 7
238000006467 substitution reaction Methods 0.000 claims description 7
108090000978 Interleukin-4 Proteins 0.000 claims description 6
108010002616 Interleukin-5 Proteins 0.000 claims description 6
108090001005 Interleukin-6 Proteins 0.000 claims description 6
210000004185 liver Anatomy 0.000 claims description 6
230000002265 prevention Effects 0.000 claims description 6
108010002352 Interleukin-1 Proteins 0.000 claims description 5
108090000177 Interleukin-11 Proteins 0.000 claims description 5
108090000176 Interleukin-13 Proteins 0.000 claims description 5
108010002350 Interleukin-2 Proteins 0.000 claims description 5
108010002335 Interleukin-9 Proteins 0.000 claims description 5
102000036693 Thrombopoietin Human genes 0.000 claims description 5
108010041111 Thrombopoietin Proteins 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
102000003812 Interleukin-15 Human genes 0.000 claims description 4
108090000172 Interleukin-15 Proteins 0.000 claims description 4
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 claims description 4
208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
102000030621 adenylate cyclase Human genes 0.000 claims description 4
108060000200 adenylate cyclase Proteins 0.000 claims description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
230000003308 immunostimulating effect Effects 0.000 claims description 4
125000002346 iodo group Chemical group I* 0.000 claims description 4
208000023275 Autoimmune disease Diseases 0.000 claims description 3
206010061598 Immunodeficiency Diseases 0.000 claims description 3
208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
230000007813 immunodeficiency Effects 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
WMMKLGOAKIPZJN-YTFOTSKYSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-3-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]propanoyl]amino]-3-sulfanylpropanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCC(=O)N1 WMMKLGOAKIPZJN-YTFOTSKYSA-N 0.000 claims description 2
HJDRXEQUFWLOGJ-AJNGGQMLSA-N Ac-Ser-Asp-Lys-Pro-OH Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(O)=O HJDRXEQUFWLOGJ-AJNGGQMLSA-N 0.000 claims description 2
108010024636 Glutathione Proteins 0.000 claims description 2
108700012920 TNF Proteins 0.000 claims description 2
230000036592 analgesia Effects 0.000 claims description 2
208000007502 anemia Diseases 0.000 claims description 2
229960003180 glutathione Drugs 0.000 claims description 2
108010031357 goralatide Proteins 0.000 claims description 2
230000002071 myeloproliferative effect Effects 0.000 claims description 2
230000036407 pain Effects 0.000 claims description 2
210000003954 umbilical cord Anatomy 0.000 claims description 2
VDMABHYXBULDGN-LAEOZQHASA-N Gln-Val-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O VDMABHYXBULDGN-LAEOZQHASA-N 0.000 claims 1
210000004524 haematopoietic cell Anatomy 0.000 claims 1
239000003112 inhibitor Substances 0.000 abstract description 36
230000022131 cell cycle Effects 0.000 abstract description 22
238000011084 recovery Methods 0.000 abstract description 11
238000002955 isolation Methods 0.000 abstract description 2
230000001105 regulatory effect Effects 0.000 abstract description 2
230000000694 effects Effects 0.000 description 72
210000001185 bone marrow Anatomy 0.000 description 71
108090000623 proteins and genes Proteins 0.000 description 61
241000699670 Mus sp. Species 0.000 description 57
235000001014 amino acid Nutrition 0.000 description 41
229940024606 amino acid Drugs 0.000 description 39
102000004169 proteins and genes Human genes 0.000 description 34
238000001727 in vivo Methods 0.000 description 31
235000018102 proteins Nutrition 0.000 description 31
239000002609 medium Substances 0.000 description 30
230000035755 proliferation Effects 0.000 description 29
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
229940127240 opiate Drugs 0.000 description 24
238000000746 purification Methods 0.000 description 24
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 23
229960001712 testosterone propionate Drugs 0.000 description 23
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 22
241000699666 Mus <mouse, genus> Species 0.000 description 22
229960002949 fluorouracil Drugs 0.000 description 22
239000000499 gel Substances 0.000 description 21
208000032839 leukemia Diseases 0.000 description 21
102000000013 Chemokine CCL3 Human genes 0.000 description 20
230000001351 cycling effect Effects 0.000 description 20
101710155856 C-C motif chemokine 3 Proteins 0.000 description 18
229940127089 cytotoxic agent Drugs 0.000 description 18
229940076264 interleukin-3 Drugs 0.000 description 18
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 18
239000000047 product Substances 0.000 description 18
241001465754 Metazoa Species 0.000 description 17
238000011534 incubation Methods 0.000 description 17
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
238000000338 in vitro Methods 0.000 description 16
230000007774 longterm Effects 0.000 description 16
210000003643 myeloid progenitor cell Anatomy 0.000 description 16
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 14
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 14
241001529936 Murinae Species 0.000 description 14
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 14
239000002246 antineoplastic agent Substances 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000012634 fragment Substances 0.000 description 14
230000005764 inhibitory process Effects 0.000 description 14
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
238000001959 radiotherapy Methods 0.000 description 14
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
229960004127 naloxone Drugs 0.000 description 13
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 13
238000011533 pre-incubation Methods 0.000 description 13
102000001490 Opioid Peptides Human genes 0.000 description 12
108010093625 Opioid Peptides Proteins 0.000 description 12
238000010322 bone marrow transplantation Methods 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
239000003399 opiate peptide Substances 0.000 description 12
230000004083 survival effect Effects 0.000 description 12
229940104230 thymidine Drugs 0.000 description 12
230000004069 differentiation Effects 0.000 description 11
150000003278 haem Chemical class 0.000 description 11
230000011132 hemopoiesis Effects 0.000 description 11
210000005259 peripheral blood Anatomy 0.000 description 11
239000011886 peripheral blood Substances 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
102400001111 Nociceptin Human genes 0.000 description 10
108090000622 Nociceptin Proteins 0.000 description 10
108090000137 Opioid Receptors Proteins 0.000 description 10
102000003840 Opioid Receptors Human genes 0.000 description 10
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
230000001464 adherent effect Effects 0.000 description 10
210000000601 blood cell Anatomy 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 10
238000004007 reversed phase HPLC Methods 0.000 description 10
UEVAHGMTRWGMTB-JBXUNAHCSA-N (2s)-6-amino-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 UEVAHGMTRWGMTB-JBXUNAHCSA-N 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
238000003556 assay Methods 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
239000003102 growth factor Substances 0.000 description 9
229960005181 morphine Drugs 0.000 description 9
239000000725 suspension Substances 0.000 description 9
238000002054 transplantation Methods 0.000 description 9
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 8
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
102100021519 Hemoglobin subunit beta Human genes 0.000 description 8
108091005904 Hemoglobin subunit beta Proteins 0.000 description 8
108010062374 Myoglobin Proteins 0.000 description 8
102100030856 Myoglobin Human genes 0.000 description 8
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 8
230000018199 S phase Effects 0.000 description 8
239000000284 extract Substances 0.000 description 8
108020001507 fusion proteins Proteins 0.000 description 8
102000037865 fusion proteins Human genes 0.000 description 8
229960003604 testosterone Drugs 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
108010094098 tyrosyl-arginyl-phenylalanyl-lysinamide Proteins 0.000 description 8
PZWWYAHWHHNCHO-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 PZWWYAHWHHNCHO-FGHAYEPSSA-N 0.000 description 7
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 7
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 7
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
239000000556 agonist Substances 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
229920000609 methyl cellulose Polymers 0.000 description 7
239000001923 methylcellulose Substances 0.000 description 7
235000010981 methylcellulose Nutrition 0.000 description 7
210000005087 mononuclear cell Anatomy 0.000 description 7
108700040302 phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide Proteins 0.000 description 7
230000007017 scission Effects 0.000 description 7
210000000952 spleen Anatomy 0.000 description 7
238000010561 standard procedure Methods 0.000 description 7
210000000689 upper leg Anatomy 0.000 description 7
239000013598 vector Substances 0.000 description 7
IDLAOWFFKWRNHB-UHFFFAOYSA-N 4,5,6,7-tetrachloroindene-1,3-dione Chemical compound ClC1=C(Cl)C(Cl)=C2C(=O)CC(=O)C2=C1Cl IDLAOWFFKWRNHB-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
102100025040 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Human genes 0.000 description 6
101710186831 Ubiquitin carboxyl-terminal hydrolase isozyme L3 Proteins 0.000 description 6
230000009471 action Effects 0.000 description 6
238000007792 addition Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000037396 body weight Effects 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
230000003021 clonogenic effect Effects 0.000 description 6
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
230000001472 cytotoxic effect Effects 0.000 description 6
230000006378 damage Effects 0.000 description 6
210000003013 erythroid precursor cell Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
238000012546 transfer Methods 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
102100026145 Transitional endoplasmic reticulum ATPase Human genes 0.000 description 5
239000008272 agar Substances 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000003636 conditioned culture medium Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000010828 elution Methods 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
108010020477 exorphins Proteins 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
229940025294 hemin Drugs 0.000 description 5
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
239000003446 ligand Substances 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
238000012216 screening Methods 0.000 description 5
238000000926 separation method Methods 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
108700043026 tyrosyl-prolyl-leucyl-glycinamide Proteins 0.000 description 5
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 4
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
108010092674 Enkephalins Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 4
229930193140 Neomycin Natural products 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 4
102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 4
239000007997 Tricine buffer Substances 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
230000032683 aging Effects 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
238000012870 ammonium sulfate precipitation Methods 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
230000001332 colony forming effect Effects 0.000 description 4
229960004397 cyclophosphamide Drugs 0.000 description 4
239000002254 cytotoxic agent Substances 0.000 description 4
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
230000000925 erythroid effect Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000012010 growth Effects 0.000 description 4
210000000777 hematopoietic system Anatomy 0.000 description 4
230000003463 hyperproliferative effect Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000010410 layer Substances 0.000 description 4
239000006166 lysate Substances 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229960004927 neomycin Drugs 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
238000007747 plating Methods 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000017854 proteolysis Effects 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
230000002629 repopulating effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 3
ZHUJMSMQIPIPTF-IBURTVSXSA-N (2r)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-IBURTVSXSA-N 0.000 description 3
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
206010002961 Aplasia Diseases 0.000 description 3
208000032467 Aplastic anaemia Diseases 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
102000011632 Caseins Human genes 0.000 description 3
108010076119 Caseins Proteins 0.000 description 3
206010010144 Completed suicide Diseases 0.000 description 3
108010065372 Dynorphins Proteins 0.000 description 3
108010049140 Endorphins Proteins 0.000 description 3
102000009025 Endorphins Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920001917 Ficoll Polymers 0.000 description 3
241000282412 Homo Species 0.000 description 3
101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 3
101000747867 Homo sapiens Upstream-binding protein 1 Proteins 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
108010004028 Leucine-2-Alanine Enkephalin Proteins 0.000 description 3
102400000988 Met-enkephalin Human genes 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108010042237 Methionine Enkephalin Proteins 0.000 description 3
102100028646 Nociceptin receptor Human genes 0.000 description 3
102100024622 Proenkephalin-B Human genes 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
241000282887 Suidae Species 0.000 description 3
102100040065 Upstream-binding protein 1 Human genes 0.000 description 3
241000251539 Vertebrata <Metazoa> Species 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
238000013459 approach Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229960004126 codeine Drugs 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
238000011393 cytotoxic chemotherapy Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 3
JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
229950004155 etorphine Drugs 0.000 description 3
CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 description 3
239000012467 final product Substances 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
231100000518 lethal Toxicity 0.000 description 3
230000001665 lethal effect Effects 0.000 description 3
210000002540 macrophage Anatomy 0.000 description 3
238000012261 overproduction Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
235000008729 phenylalanine Nutrition 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000004366 reverse phase liquid chromatography Methods 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000024642 stem cell division Effects 0.000 description 3
210000002536 stromal cell Anatomy 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GYNQVPIDAQTZOY-ROUUACIJSA-N (2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 GYNQVPIDAQTZOY-ROUUACIJSA-N 0.000 description 2
ABTNETSDXZBJTE-WLHGVMLRSA-N (e)-but-2-enedioic acid;methyl 4-[2-(3,4-dichlorophenyl)acetyl]-3-(pyrrolidin-1-ylmethyl)piperazine-1-carboxylate Chemical compound OC(=O)\C=C\C(O)=O.C1N(C(=O)OC)CCN(C(=O)CC=2C=C(Cl)C(Cl)=CC=2)C1CN1CCCC1 ABTNETSDXZBJTE-WLHGVMLRSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
101800000504 3C-like protease Proteins 0.000 description 2
238000010600 3H thymidine incorporation assay Methods 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
108700012434 CCL3 Proteins 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
108700010070 Codon Usage Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 2
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
108010065805 Interleukin-12 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
108010022337 Leucine Enkephalin Proteins 0.000 description 2
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
108091008109 Pseudogenes Proteins 0.000 description 2
102000057361 Pseudogenes Human genes 0.000 description 2
101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108010056088 Somatostatin Proteins 0.000 description 2
102000005157 Somatostatin Human genes 0.000 description 2
102000015215 Stem Cell Factor Human genes 0.000 description 2
108010039445 Stem Cell Factor Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
229960001736 buprenorphine Drugs 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
230000003750 conditioning effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
238000009109 curative therapy Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
108700023159 delta Opioid Receptors Proteins 0.000 description 2
102000048124 delta Opioid Receptors Human genes 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
229960002069 diamorphine Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229960004192 diphenoxylate Drugs 0.000 description 2
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960002428 fentanyl Drugs 0.000 description 2
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
238000007710 freezing Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
102000055647 human CSF2RB Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
229960000240 hydrocodone Drugs 0.000 description 2
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
229960001410 hydromorphone Drugs 0.000 description 2
229960001330 hydroxycarbamide Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
102000048260 kappa Opioid Receptors Human genes 0.000 description 2
URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 2
229960003406 levorphanol Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000001400 myeloablative effect Effects 0.000 description 2
210000001087 myotubule Anatomy 0.000 description 2
AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 description 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
229960003086 naltrexone Drugs 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
210000003924 normoblast Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003401 opiate antagonist Substances 0.000 description 2
238000005457 optimization Methods 0.000 description 2
229960002085 oxycodone Drugs 0.000 description 2
229960005118 oxymorphone Drugs 0.000 description 2
101800000607 p15 Proteins 0.000 description 2
229960000482 pethidine Drugs 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
229940067157 phenylhydrazine Drugs 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
239000013014 purified material Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000002994 raw material Substances 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
229960000553 somatostatin Drugs 0.000 description 2
241000894007 species Species 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000011476 stem cell transplantation Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000010257 thawing Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
230000007704 transition Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
108010012567 tyrosyl-glycyl-glycyl-phenylalanyl Proteins 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108020001588 κ-opioid receptors Proteins 0.000 description 2
UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
XJOQRTJDYAHKPY-MWSMAVIUSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-n-[(2s)-1-[[(2s)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-o Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 XJOQRTJDYAHKPY-MWSMAVIUSA-N 0.000 description 1
PAJVBIPSWDYNHN-JMJBHNTOSA-N (2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s,3r)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PAJVBIPSWDYNHN-JMJBHNTOSA-N 0.000 description 1
MVUYXNQARFGHMJ-DCSNJQJVSA-N (2s)-2-amino-n-[(2r)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 MVUYXNQARFGHMJ-DCSNJQJVSA-N 0.000 description 1
AGTSSZRZBSNTGQ-ITZCFHCWSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomet Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 AGTSSZRZBSNTGQ-ITZCFHCWSA-N 0.000 description 1
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
NWFLONJLUJYCNS-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1CC(C(O)=O)NC(=O)CNC(=O)CNC(=O)C(N)CC1=CC=CC=C1 NWFLONJLUJYCNS-UHFFFAOYSA-N 0.000 description 1
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
241000256844 Apis mellifera Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101500025132 Bos taurus Ubiquitin Proteins 0.000 description 1
101500027500 Bos taurus Ubiquitin Proteins 0.000 description 1
101500027539 Bos taurus Ubiquitin Proteins 0.000 description 1
101500028979 Bos taurus Ubiquitin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000225069 Calyptocephallela gayi Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108050000299 Chemokine receptor Proteins 0.000 description 1
102000009410 Chemokine receptor Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
241000252206 Cypriniformes Species 0.000 description 1
102100025287 Cytochrome b Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010075028 Cytochromes b Proteins 0.000 description 1
108010003212 D-Ala(2),MePhe(4),Met(0)-ol-enkephalin Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical class C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 description 1
102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
206010073306 Exposure to radiation Diseases 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108010044495 Fetal Hemoglobin Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010068370 Glutens Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
101001035503 Homo sapiens Hemoglobin subunit delta Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000049772 Interleukin-16 Human genes 0.000 description 1
101800003050 Interleukin-16 Proteins 0.000 description 1
102100039064 Interleukin-3 Human genes 0.000 description 1
208000032177 Intestinal Polyps Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
108010054278 Lac Repressors Proteins 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001440178 Massala Species 0.000 description 1
IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
230000004988 N-glycosylation Effects 0.000 description 1
SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 1
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
239000008896 Opium Substances 0.000 description 1
102000016978 Orphan receptors Human genes 0.000 description 1
108070000031 Orphan receptors Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000006994 Precancerous Conditions Diseases 0.000 description 1
208000007541 Preleukemia Diseases 0.000 description 1
108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010061926 Purulence Diseases 0.000 description 1
102400000235 Rimorphin Human genes 0.000 description 1
101800001440 Rimorphin Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
101001083338 Sus scrofa Hemoglobin subunit alpha Proteins 0.000 description 1
101000990253 Sus scrofa Hemoglobin subunit beta Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
102100036407 Thioredoxin Human genes 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
102000005937 Tropomyosin Human genes 0.000 description 1
108010030743 Tropomyosin Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
HPYDSVWYXXKHRD-VIFPVBQESA-N Tyr-Gly Chemical group [O-]C(=O)CNC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 HPYDSVWYXXKHRD-VIFPVBQESA-N 0.000 description 1
VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
PAJVBIPSWDYNHN-UHFFFAOYSA-N Tyr-Pro-Trp-Thr-Gln-Arg-Phe Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCC(N)=O)NC(=O)C(C(O)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCCN1C(=O)C(N)CC1=CC=C(O)C=C1 PAJVBIPSWDYNHN-UHFFFAOYSA-N 0.000 description 1
102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 1
108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
150000001295 alanines Chemical class 0.000 description 1
229960001391 alfentanil Drugs 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
229960001349 alphaprodine Drugs 0.000 description 1
UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000002617 apheresis Methods 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
108010093581 aspartyl-proline Proteins 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
244000309466 calf Species 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000006652 catabolic pathway Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
108010042445 cell-binding peptide P-15 Proteins 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000002791 cfu-m Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000027288 circadian rhythm Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000009096 combination chemotherapy Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000039 congener Substances 0.000 description 1
208000035623 congenital anemia Diseases 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000011033 desalting Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960004193 dextropropoxyphene Drugs 0.000 description 1
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
229960000920 dihydrocodeine Drugs 0.000 description 1
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000001339 epidermal cell Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000021312 gluten Nutrition 0.000 description 1
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
108010036302 hemoglobin AS Proteins 0.000 description 1
108010022155 hemoglobin Portland Proteins 0.000 description 1
108010047910 hemorphin 7 Proteins 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
102000055276 human IL3 Human genes 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000000917 hyperalgesic effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000004898 kneading Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
229960000263 levallorphan Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
108010019084 mastoparan Proteins 0.000 description 1
MASXKPLGZRMBJF-MVSGICTGSA-N mastoparan Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O MASXKPLGZRMBJF-MVSGICTGSA-N 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
229960000365 meptazinol Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960001797 methadone Drugs 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
108010083475 myelopeptides Proteins 0.000 description 1
229960000805 nalbuphine Drugs 0.000 description 1
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
229960000938 nalorphine Drugs 0.000 description 1
239000002353 niosome Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
108010020615 nociceptin receptor Proteins 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
239000003402 opiate agonist Substances 0.000 description 1
230000000945 opiatelike Effects 0.000 description 1
229960001027 opium Drugs 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
150000002994 phenylalanines Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000008288 physiological mechanism Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920001987 poloxamine Polymers 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
108010094020 polyglycine Proteins 0.000 description 1
229920000232 polyglycine polymer Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229950008885 polyglycolic acid Drugs 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
108010034422 pre-prodynorphin Proteins 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
108010074732 preproenkephalin Proteins 0.000 description 1
230000002400 pro-nociceptive effect Effects 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000007065 protein hydrolysis Effects 0.000 description 1
238000000734 protein sequencing Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001950 radioprotection Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000012807 shake-flask culturing Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000012868 site-directed mutagenesis technique Methods 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010911 splenectomy Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
230000023895 stem cell maintenance Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000007801 sublethal irradiation Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
108010020532 tyrosyl-proline Proteins 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
235000014393 valine Nutrition 0.000 description 1
150000003680 valines Chemical class 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
235000021249 α-casein Nutrition 0.000 description 1
235000021247 β-casein Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO19984628A 1996-04-03 1998-10-02 Polypeptider og peptider som omfatter en hemoglobin-alfa-kjede eller deler derav, farmasoytiske blandinger som omfatter dem, samt anvendelser og fremgangsmater som involverer stamcelleproliferasjonsinhiberende og -stimulerende mengder av polypeptidene og peptidene. NO323610B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/627,173 US5861483A (en)	1996-04-03	1996-04-03	Inhibitor of stem cell proliferation and uses thereof
PCT/US1997/005601 WO1997036922A1 (en)	1996-04-03	1997-04-03	Inhibitor and stimulator of stem cell proliferation and uses thereof

Publications (3)

Publication Number	Publication Date
NO984628D0 NO984628D0 (no)	1998-10-02
NO984628L NO984628L (no)	1998-12-01
NO323610B1 true NO323610B1 (no)	2007-06-18

Family

ID=24513524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19984628A NO323610B1 (no)	1996-04-03	1998-10-02	Polypeptider og peptider som omfatter en hemoglobin-alfa-kjede eller deler derav, farmasoytiske blandinger som omfatter dem, samt anvendelser og fremgangsmater som involverer stamcelleproliferasjonsinhiberende og -stimulerende mengder av polypeptidene og peptidene.

Country Status (16)

Country	Link
US (4)	US5861483A (ru)
EP (2)	EP0891377B1 (ru)
JP (3)	JP4241927B2 (ru)
KR (1)	KR20040088588A (ru)
CN (2)	CN1264856C (ru)
AT (1)	ATE311406T1 (ru)
AU (1)	AU727023B2 (ru)
CA (1)	CA2249716A1 (ru)
DE (1)	DE69734766T2 (ru)
ES (1)	ES2252781T3 (ru)
IL (2)	IL126395A0 (ru)
NO (1)	NO323610B1 (ru)
NZ (1)	NZ331895A (ru)
RU (1)	RU2292352C9 (ru)
UA (2)	UA74128C2 (ru)
WO (1)	WO1997036922A1 (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU694111B2 (en)	1993-03-31	1998-07-16	Pro-Neuron, Inc.	Inhibitor of stem cell proliferation and uses thereof
US5939391A (en) *	1993-03-31	1999-08-17	Pro-Neuron, Inc.	Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
US6610654B2 (en)	1993-03-31	2003-08-26	Wellstat Therapeutics Corporation	Inhibitor of stem cell proliferation and uses thereof
US5861483A (en)	1996-04-03	1999-01-19	Pro-Neuron, Inc.	Inhibitor of stem cell proliferation and uses thereof
AUPO089396A0 (en) *	1996-07-09	1996-08-01	Howard Florey Institute Of Experimental Physiology And Medicine	Neuroactive peptide
EP0939644B1 (en) *	1996-08-27	2004-01-14	Hemosol Inc.	Enhanced stimulation of erythropoiesis
DE19708454A1 (de) *	1997-02-17	1998-08-27	Schering Ag	Die Proliferation von Zellen inhibierendes Peptid und dessen Verwendung
US8197430B1 (en) *	1998-05-22	2012-06-12	Biopheresis Technologies, Inc.	Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) *	1998-05-22	2003-09-16	Biopheresis Technologies, Llc.	Method and compositions for treatment of cancers
ATE284220T1 (de) *	1999-02-03	2004-12-15	Idm Immuno Designed Molecules	Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
US6379708B1 (en) *	1999-11-20	2002-04-30	Cytologic, Llc	Method for enhancing immune responses in mammals
EP1322323A4 (en)	2000-09-11	2004-07-28	Therapro Technologies Inc	THIONIN AS AN ANTINEOPLASTIC AND IMMUNO-STIMULATING AGENT
AU2002241859B2 (en)	2001-01-10	2007-07-19	St. Vincent's Institute Of Medical Research	sFRP and peptide motifs that interact with sFRP and methods of their use
SG142165A1 (en) *	2001-07-13	2008-05-28	Cms Peptides Patent Holding Co	Biologically active peptides
CN1216070C (zh) *	2001-07-13	2005-08-24	一泰医药研究（深圳）有限公司	序列号20的生物活性肽
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
RU2245162C2 (ru) *	2003-01-04	2005-01-27	Козлов Владимир Александрович	Способ терапии инфаркта миокарда
WO2005107802A2 (en) *	2004-04-30	2005-11-17	Biopheresis Technologies, Llc	Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
FR2872040B1 (fr) *	2004-06-23	2006-09-22	Centre Nat Rech Scient Cnrse	Utilisation cosmetique d'au moins un tetrapeptide naturel ac-n-ser-asp-lys-pro- ou un de ses analogues en tant qu'agent antivieillissement et restructurant de la peau
EP1778271B1 (en) *	2004-08-18	2008-10-22	IPF Pharmaceuticals GmbH	Peptides for the treatment of herpes virus infections
US7850960B2 (en) *	2004-12-30	2010-12-14	University Of Washington	Methods for regulation of stem cells
KR100621354B1 (ko) *	2005-06-14	2006-09-08	광주과학기술원	유비퀴틴을 이용한 아밀로이드-베타 펩티드의 제조방법
NZ591827A (en)	2005-07-26	2012-10-26	Cms Peptides Patent Holding Company Ltd	Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
US20070065514A1 (en) *	2005-09-22	2007-03-22	Howell Mark D	Method for enhancing immune responses in mammals
CN1994464B (zh) *	2005-12-31	2010-05-05	中国科学院大连化学物理研究所	一种血管紧张素i转换酶抑制剂及其应用
RU2317074C1 (ru) *	2006-03-16	2008-02-20	Общество с ограниченной ответственностью "МБФ"	Ингибитор дифференцировки кроветворных клеток-предшественников
US20080075690A1 (en) *	2006-09-22	2008-03-27	Mark Douglas Howell	Method for enhancing immune responses in mammals
WO2008039874A2 (en)	2006-09-26	2008-04-03	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
WO2008144019A2 (en) *	2007-05-18	2008-11-27	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Suppression of allergic inflammation by ascaris heme-binding protein (hbp)
US20100204149A1 (en) *	2007-09-11	2010-08-12	Dorian Bevec	Use of octreotide as a therapeutic agent
KR20100069651A (ko) *	2007-09-11	2010-06-24	몬도바이오테크 래보래토리즈 아게	Ｈｃｍｖ 감염의 치료를 위한 치료제로서의 ｂｕｂｕｃ 및 임의의 ｅａａ－ｍａｒｔ１（２６－３５）의 용도
CA2698666A1 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
PT2113253E (pt) *	2008-04-30	2010-06-15	Immatics Biotechnologies Gmbh	Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
RU2374262C1 (ru) *	2008-05-22	2009-11-27	Ибмед Холдингс Лимитед	Олигопептид, обладающий активностью фактора стволовых клеток csf по отношению к дифференцировке тимоцитов
CN102209552A (zh) *	2008-11-07	2011-10-05	联合技术Ut股份公司	含有白介素-1和肽的组合物
RU2412708C2 (ru) *	2008-11-27	2011-02-27	Федеральное Государственное Учреждение "Кировский Научно-Исследовательский Институт Гематологии И Переливания Крови Федерального Агентства По Высокотехнологичной Медицинской Помощи"	Способ индукции ремиссии у больных приобретенной апластической анемией
WO2010091052A2 (en)	2009-02-03	2010-08-12	Children's Medical Center Corporation	Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en)	2009-02-03	2010-08-26	Children's Medical Center Corporation	Methods for enhancing hematopoietic stem/progenitor cell engraftment
EA201101639A1 (ru) *	2009-05-20	2012-06-29	Юниверсите Де Женев	Ингибиторы митохондриальной активности клеток, инициирующих рак, и их применение
RU2395251C1 (ru) *	2009-05-25	2010-07-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ стимулирования миелопоэза животных
US20110070269A1 (en) *	2009-09-24	2011-03-24	Therapro Technologies, Inc.	Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof
RU2452501C2 (ru) *	2010-08-31	2012-06-10	Александр Владимирович Балюра	Сенситин для эритроцитарного диагностикума для диагностики злокачественных новообразований и способ его получения, эритроцитарный диагностикум для диагностики злокачественных новообразований и способ его получения и способ диагностики наличия злокачественных новообразований с использованием указанного эритроцитарного диагностикума
AU2010365057B2 (en) *	2010-12-08	2016-12-22	Viacyte, Inc.	Agents and methods for inhibiting human pluripotent stem cell growth
WO2012159044A1 (en) *	2011-05-18	2012-11-22	Wellstat Therapeutics Corporation	Stem cell mobilization and tissue repair and regeneration
US9428552B2 (en)	2012-11-19	2016-08-30	Wellstat Therapeutics Corporation	Stem cell mobilization and tissue repair and regeneration
CN103804484B (zh) *	2014-01-24	2016-03-16	南京必优康生物技术有限公司	一种网红细胞生长因子及其制备方法和应用
CN106317177A (zh) *	2015-06-23	2017-01-11	首都医科大学	Gly-Phe-Pro,其合成,活性和应用
CN107899001B (zh) *	2017-05-16	2021-08-06	陈娟娟	Notch配体蛋白在制备治疗肿瘤化疗导致骨髓抑制药物方面及早期预后判断方面的应用
CN109293737B (zh) *	2018-09-27	2020-10-27	华南理工大学	一种抗皮肤衰老的四肽及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1142466A (en) *	1979-01-09	1983-03-08	National Research Development Corporation	Cell lines
US4683194A (en) *	1984-05-29	1987-07-28	Cetus Corporation	Method for detection of polymorphic restriction sites and nucleic acid sequences
US5132213A (en) *	1986-10-02	1992-07-21	Massachusetts Institute Of Technology	Method for producing proteins and polypeptides using ubiquitin fusions
US5196321A (en)	1986-10-02	1993-03-23	Massachusetts Institute Of Technology	Methods for in vitro cleavage of ubiquitin fusion proteins
GB8711614D0 (en) *	1987-05-16	1987-06-24	Medical Res Council	Proteins
US5449759A (en) *	1987-05-16	1995-09-12	Somatogen, Inc.	Hemoglobins with intersubunit desulfide bonds
US5545727A (en) *	1989-05-10	1996-08-13	Somatogen, Inc.	DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
DE69028448T2 (de) *	1989-05-10	1997-02-06	Medical Research Council, London	Herstellung von Hämoglobin und Analogen davon durch Bakterien oder Hefen
CA2064558C (en) *	1989-09-25	2001-01-30	Ian B. Pragnell	Method for inhibiting growth of stem cells
EP0531404B1 (en) *	1990-05-09	1995-04-19	Massachusetts Institute Of Technology	Ubiquitin-specific protease
US5239061A (en) *	1990-06-20	1993-08-24	Research Corporation Technologies, Inc.	Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
CA2098818A1 (en) *	1990-12-20	1992-06-21	Tim Townes	Transgenic, cross-linked hemoglobin
AU2140492A (en)	1991-05-14	1992-12-30	Biopure Corporation	Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5334706A (en)	1992-01-30	1994-08-02	Baxter International	Administration of low dose hemoglobin to increase perfusion
JPH07507921A (ja)	1992-06-12	1995-09-07	ディーエヌエックス　コーポレーション	トランスジェニックブタにおけるヒトヘモグロビンの生産
US5786334A (en) *	1992-08-14	1998-07-28	Technology Resources International, Inc.	Hexapeptide having immunostimulatory activity
DE4228458A1 (de) *	1992-08-27	1994-06-01	Beiersdorf Ag	Multicistronische Expressionseinheiten und deren Verwendung
AU694111B2 (en)	1993-03-31	1998-07-16	Pro-Neuron, Inc.	Inhibitor of stem cell proliferation and uses thereof
US5939391A (en)	1993-03-31	1999-08-17	Pro-Neuron, Inc.	Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
US6610654B2 (en) *	1993-03-31	2003-08-26	Wellstat Therapeutics Corporation	Inhibitor of stem cell proliferation and uses thereof
US5631219A (en)	1994-03-08	1997-05-20	Somatogen, Inc.	Method of stimulating hematopoiesis with hemoglobin
FR2719240B1 (fr) *	1994-04-29	1996-06-07	Elf Antar France	Procédé de traitement des suspensions huileuses.
US5861483A (en) *	1996-04-03	1999-01-19	Pro-Neuron, Inc.	Inhibitor of stem cell proliferation and uses thereof
US6280739B1 (en) *	1996-04-18	2001-08-28	Genetics Institute, Inc.	Method of inhibiting angiogenesis using secreted proteins

1996
- 1996-04-03 US US08/627,173 patent/US5861483A/en not_active Expired - Fee Related
1997
- 1997-03-04 UA UA98105223A patent/UA74128C2/ru unknown
- 1997-04-03 KR KR10-2004-7014590A patent/KR20040088588A/ko not_active Ceased
- 1997-04-03 DE DE69734766T patent/DE69734766T2/de not_active Expired - Lifetime
- 1997-04-03 CA CA002249716A patent/CA2249716A1/en not_active Abandoned
- 1997-04-03 AT AT97920117T patent/ATE311406T1/de not_active IP Right Cessation
- 1997-04-03 EP EP97920117A patent/EP0891377B1/en not_active Expired - Lifetime
- 1997-04-03 IL IL12639597A patent/IL126395A0/xx not_active IP Right Cessation
- 1997-04-03 US US08/832,443 patent/US6784155B1/en not_active Expired - Fee Related
- 1997-04-03 CN CNB2004100074707A patent/CN1264856C/zh not_active Expired - Fee Related
- 1997-04-03 NZ NZ331895A patent/NZ331895A/xx unknown
- 1997-04-03 EP EP05019956A patent/EP1820805A3/en not_active Withdrawn
- 1997-04-03 JP JP53561197A patent/JP4241927B2/ja not_active Expired - Fee Related
- 1997-04-03 RU RU98119712/04A patent/RU2292352C9/ru active
- 1997-04-03 AU AU24391/97A patent/AU727023B2/en not_active Ceased
- 1997-04-03 WO PCT/US1997/005601 patent/WO1997036922A1/en not_active Ceased
- 1997-04-03 CN CNB971950954A patent/CN1174996C/zh not_active Expired - Fee Related
- 1997-04-03 ES ES97920117T patent/ES2252781T3/es not_active Expired - Lifetime
1998
- 1998-10-02 NO NO19984628A patent/NO323610B1/no not_active IP Right Cessation
2004
- 2004-02-12 US US10/776,172 patent/US7115267B2/en not_active Expired - Fee Related
- 2004-04-06 UA UA20040402942A patent/UA85036C2/ru unknown
2006
- 2006-03-23 US US11/386,736 patent/US20060166863A1/en not_active Abandoned
- 2006-06-29 IL IL176642A patent/IL176642A0/en unknown
2008
- 2008-08-04 JP JP2008201331A patent/JP2009013178A/ja not_active Withdrawn
2011
- 2011-10-13 JP JP2011225796A patent/JP2012046537A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
NO984628L (no)	1998-12-01
US7115267B2 (en)	2006-10-03
EP0891377B1 (en)	2005-11-30
AU727023B2 (en)	2000-11-30
NO984628D0 (no)	1998-10-02
RU2292352C9 (ru)	2007-05-10
CN1264856C (zh)	2006-07-19
IL176642A0 (en)	2006-10-31
AU2439197A (en)	1997-10-22
JP2000508633A (ja)	2000-07-11
RU2292352C2 (ru)	2007-01-27
CN1174996C (zh)	2004-11-10
US20060166863A1 (en)	2006-07-27
EP0891377A4 (en)	2003-01-02
JP2012046537A (ja)	2012-03-08
CA2249716A1 (en)	1997-10-09
KR20040088588A (ko)	2004-10-16
WO1997036922A1 (en)	1997-10-09
JP2009013178A (ja)	2009-01-22
NZ331895A (en)	2000-07-28
IL126395A0 (en)	1999-05-09
CN1541706A (zh)	2004-11-03
ES2252781T3 (es)	2006-05-16
EP1820805A3 (en)	2007-11-07
US5861483A (en)	1999-01-19
DE69734766T2 (de)	2006-09-14
HK1069985A1 (en)	2005-06-10
UA74128C2 (ru)	2005-11-15
DE69734766D1 (de)	2006-01-05
JP4241927B2 (ja)	2009-03-18
EP0891377A1 (en)	1999-01-20
US20040167060A1 (en)	2004-08-26
CN1220670A (zh)	1999-06-23
ATE311406T1 (de)	2005-12-15
UA85036C2 (ru)	2008-12-25
US6784155B1 (en)	2004-08-31
EP1820805A2 (en)	2007-08-22

Legal Events

Date	Code	Title	Description
2010-11-29	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6784155B1 (en)	2004-08-31	Inhibitor and stimulator of stem cell proliferation and uses thereof
WO1997036922A9 (en)	1997-12-18	Inhibitor and stimulator of stem cell proliferation and uses thereof
JP4188279B2 (ja)	2008-11-26	幹細胞増殖インヒビターおよびその使用
US6610654B2 (en)	2003-08-26	Inhibitor of stem cell proliferation and uses thereof
AU768081B2 (en)	2003-12-04	Inhibitor and stimulator of stem cell proliferation and uses thereof
KR100619599B1 (ko)	2007-03-02	간세포증식의억제제및자극제및그것들의용도
NZ504512A (en)	2001-10-26	Peptide from alpha-hemoglobin as a stimulator of stem cell proliferation and used thereof
EP1362596A2 (en)	2003-11-19	Inhibitor of stem cell proliferation and uses thereof
MXPA98008178A (es)	1999-09-01	Inhibidor y estimulador de la proliferación de células totipotentes y sus usos
HK1006642B (en)	2008-03-14	Inhibitor of stem cell proliferation and uses thereof